GLP-1 analogs are clinically effective in treating type 2 diabetes and obesity4, but they have been reported to be associated with adverse events, including nausea, vomiting, diarrhea, and gallbladder issues4–6. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.